Zoledronic acid injection prevents bone loss in spinal cord injury patients
Not Applicable
Completed
- Conditions
- Health Condition 1: null- Spinal cord injury with neurological deficit
- Registration Number
- CTRI/2018/03/012408
- Lead Sponsor
- Dr Satyaranjan Sethi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 60
Inclusion Criteria
1. SCI patients
2. ASIA Impairment Scale A,B,C
3. Age over 18years
4. Less than 3months from date of trauma
Exclusion Criteria
1. Hypocalcaemia (Serum Calcium < 8.5mg %)
2. Vitamin-D deficiency (Serum 25-hydroxy vitamin-D < 25nmol/L)
3. Significant renal impairment (Creatinine clearance < 30ml/min)
4. Any history of allergic reaction to bisphosphonates
5. History of iritis, uveitis, psychiatric illness
6. Female subjects who are pregnant, lactating or premenopausal women planning to conceive
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To assess magnitude of bone loss at hip and forearm following Spinal cord injury by bone mineral density by DEXA scanTimepoint: Baseline at entry into study, 3 months, 6 months and 12 months follow up
- Secondary Outcome Measures
Name Time Method To study the effect of early administration of Zoledronic acid on prevention of bone loss at hip and forearm in Spinal cord injuryTimepoint: Baseline, 3 months, 6 months and 12 months